News

Month Year

Month Year

Oct 29, 2021

Libtayo® (cemiplimab) approved in Canada for the first-line treatment of adult patients with non-small cell lung cancer expressing PD-L1 in ≥ 50% of tumour cells with no EGFR, ALK or ROS1 aberrations
Oct 13, 2021

New SARCLISA® (isatuximab for injection) Combination Now Approved by Health Canada for Adults with Relapsed and/or Refractory Multiple Myeloma
Jul 22, 2021

DUPIXENT® (dupilumab injection) receives positive recommendation from CADTH and INESSS for the treatment of severe asthma
Jul 2, 2021

Sanofi Canada continues to invest in modern diabetes research to improve outcomes for people living with diabetes
Jun 28, 2021

New Soliqua®* data shows improved blood sugar control without weight gain versus premixed insulin

Show per page